Literature DB >> 29454662

Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson's disease.

Andreas Schwiertz1, Jörg Spiegel2, Ulrich Dillmann2, David Grundmann3, Jan Bürmann2, Klaus Faßbender2, Karl-Herbert Schäfer3, Marcus M Unger4.   

Abstract

BACKGROUND/
OBJECTIVE: Intestinal inflammation and increased intestinal permeability (both possibly fueled by dysbiosis) have been suggested to be implicated in the multifactorial pathogenesis of Parkinson's disease (PD). The objective of the current study was to investigate whether fecal markers of inflammation and impaired intestinal barrier function corroborate this pathogenic aspect of PD.
METHODS: In a case-control study, we quantitatively analyzed established fecal markers of intestinal inflammation (calprotectin and lactoferrin) and fecal markers of intestinal permeability (alpha-1-antitrypsin and zonulin) in PD patients (n = 34) and controls (n = 28, group-matched for age) by enzyme-linked immunosorbent assay. The study design controlled for potential confounding factors.
RESULTS: Calprotectin, a fecal marker of intestinal inflammation, and two fecal markers of increased intestinal permeability (alpha-1-antitrypsin and zonulin) were significantly elevated in PD patients compared to age-matched controls. Lactoferrin, as a second fecal marker of intestinal inflammation, showed a non-significant trend towards elevated concentrations in PD patients. None of the four fecal markers correlated with disease severity, PD subtype, dopaminergic therapy, or presence of constipation.
CONCLUSIONS: Fecal markers reflecting intestinal inflammation and increased intestinal permeability have been primarily investigated in inflammatory bowel disease so far. Our data indicate that calprotectin, alpha-1-antitrypsin and zonulin could be useful non-invasive markers in PD as well. Even though these markers are not disease-specific, they corroborate the hypothesis of an intestinal inflammation as contributing factor in the pathogenesis of PD. Further investigations are needed to determine whether calprotectin, alpha-1-antitrypsin and zonulin can be used to define PD subgroups and to monitor the effect of interventions in PD.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alpha-1-antitrypsin; Calprotectin; Intestinal inflammation; Lactoferrin; Parkinson's disease; Zonulin

Mesh:

Substances:

Year:  2018        PMID: 29454662     DOI: 10.1016/j.parkreldis.2018.02.022

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  66 in total

Review 1.  Imaging the Autonomic Nervous System in Parkinson's Disease.

Authors:  Karoline Knudsen; Per Borghammer
Journal:  Curr Neurol Neurosci Rep       Date:  2018-09-19       Impact factor: 5.081

Review 2.  Disorders of the enteric nervous system - a holistic view.

Authors:  Beate Niesler; Stefanie Kuerten; I Ekin Demir; Karl-Herbert Schäfer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-01-29       Impact factor: 46.802

Review 3.  Is Parkinson's disease a chronic low-grade inflammatory bowel disease?

Authors:  Malvyne Rolli-Derkinderen; Laurène Leclair-Visonneau; Arnaud Bourreille; Emmanuel Coron; Michel Neunlist; Pascal Derkinderen
Journal:  J Neurol       Date:  2019-04-12       Impact factor: 4.849

4.  Cross-Reactivity and Sequence Homology Between Alpha-Synuclein and Food Products: A Step Further for Parkinson's Disease Synucleinopathy.

Authors:  Aristo Vojdani; Aaron Lerner; Elroy Vojdani
Journal:  Cells       Date:  2021-05-05       Impact factor: 6.600

Review 5.  Parkinson's disease: Are gut microbes involved?

Authors:  Yogesh Bhattarai; Purna C Kashyap
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-09-02       Impact factor: 4.052

6.  MitoPark transgenic mouse model recapitulates the gastrointestinal dysfunction and gut-microbiome changes of Parkinson's disease.

Authors:  Shivani Ghaisas; Monica R Langley; Bharathi N Palanisamy; Somak Dutta; Kirthi Narayanaswamy; Paul J Plummer; Souvarish Sarkar; Muhammet Ay; Huajun Jin; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Neurotoxicology       Date:  2019-09-07       Impact factor: 4.294

7.  The Role of Ames Dwarfism and Calorie Restriction on Gut Microbiota.

Authors:  Denise S Wiesenborn; Eric J C Gálvez; Lina Spinel; Berta Victoria; Brittany Allen; Augusto Schneider; Adam Gesing; Khalid A Al-Regaiey; Till Strowig; Karl-Herbert Schäfer; Michal M Masternak
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-06-18       Impact factor: 6.053

8.  Oral Dysbiosis and Inflammation in Parkinson's Disease.

Authors:  Vanessa Fleury; Alkisti Zekeridou; Vladimir Lazarevic; Nadia Gaïa; Catherine Giannopoulou; Laurence Genton; José Cancela; Myriam Girard; Rachel Goldstein; Julien F Bally; Andrea Mombelli; Jacques Schrenzel; Pierre R Burkhard
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

Review 9.  Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis.

Authors:  Yareth Gopar-Cuevas; Ana P Duarte-Jurado; Rosa N Diaz-Perez; Odila Saucedo-Cardenas; Maria J Loera-Arias; Roberto Montes-de-Oca-Luna; Humberto Rodriguez-Rocha; Aracely Garcia-Garcia
Journal:  Mol Neurobiol       Date:  2021-08-05       Impact factor: 5.590

Review 10.  Immune-microbiome interplay and its implications in neurodegenerative disorders.

Authors:  Ankit Uniyal; Vineeta Tiwari; Mousmi Rani; Vinod Tiwari
Journal:  Metab Brain Dis       Date:  2021-08-06       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.